Drugmaker AbbVie Inc. agreed to acquire cancer-drug developer Stemcentrx Inc. for $5.8 billion.
With the purchase, AbbVie would gain access to Stemcentrx’s lung-cancer treatment drug known as Rova-T, as well as other experimental drugs.
Currently, AbbVie’s cancer-drug lineup only includes blood cancers. With the addition of Stemcentrx, it would add treatments for tumors in solid organs.
Read more from
The Wall Street Journal.